seizpat 150 mg tabletki powlekane
viatris ltd - lacosamidum - tabletki powlekane - 150 mg
seizpat 200 mg tabletki powlekane
viatris ltd - lacosamidum - tabletki powlekane - 200 mg
endofemine 2 mg tabletki
viatris ltd - dienogestum - tabletki - 2 mg
anidulafungin mylan 100 mg proszek do sporządzania koncentratu roztworu do infuzji
viatris ltd - anidulafunginum - proszek do sporządzania koncentratu roztworu do infuzji - 100 mg
amylan es 600 mg/5 ml + 42,9 mg/5 ml proszek do sporządzania zawiesiny doustnej
viatris ltd - amoxicillinum + acidum clavulanicum - proszek do sporządzania zawiesiny doustnej - 600 mg/5 ml + 42,9 mg/5 ml
voriconazole mylan 200 mg tabletki powlekane
viatris ltd - voriconazolum - tabletki powlekane - 200 mg
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rywaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - Środki przeciwzakrzepowe - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
dymol (137 mcg + 50 mcg)/dawkę donosową aerozol do nosa, zawiesina
viatris ltd - azelastyny chlorowodorek + flutykazonu propionian - aerozol do nosa, zawiesina - (137 mcg + 50 mcg)/dawkę donosową
banxiol 2,5 mg tabletki powlekane
viatris ltd - apixaban - tabletki powlekane - 2,5 mg
banxiol 5 mg tabletki powlekane
viatris ltd - apixabanum - tabletki powlekane - 5 mg